According to Zhitong Finance App, Haichen Pharmaceutical (300584.SZ) released its report for the third quarter of 2026. The company achieved operating income of 615 million yuan in the first three quarters, up 30.49% year on year; net profit attributable to shareholders of listed companies was 62.2556 million yuan, up 90.51% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 666.975 million yuan, an increase of 125.76% year on year; basic earnings per share were 0.5188 yuan.

The main reason for the increase in the company's revenue in the first three quarters was due to an increase in revenue after mass production of the subsidiary Anqing Huichen lithium battery materials business during the reporting period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.